Benefits of different drug formulations in psychopharmacology

European Neuropsychopharmacology

Volumn 13, Issue SUPPL. 3, 2003, Pages 77-84

  Frijlink, Henderik W ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Compliance; Drug delivery systems; Drug formulations; Mirtazapine SolTab ; Orally disintegrating dosage forms; RemeronSolTab ; Therapeutic efficacy

Indexed keywords

AMFEBUTAMONE; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; COLISTIN; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETONOGESTREL; FLUPENTIXOL; FLUPHENAZINE; GESTAGEN; HALOPERIDOL; IMMUNOSUPPRESSIVE AGENT; INSULIN; LEVONORGESTREL; MIRTAZAPINE; MIRTRAZAPINE SOLTAB; OMEPRAZOLE; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TOBRAMYCIN; VENLAFAXINE; VERAPAMIL;

ALLERGY; ASTHMA; BIOEQUIVALENCE; CANCER; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONOTHERAPY; CIRCADIAN RHYTHM; CIRCADIAN RHYTHM SLEEP DISORDER; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CYSTIC FIBROSIS; DIABETES MELLITUS; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG RELEASE; EPILEPSY; GLAUCOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INHALER; KIDNEY TRANSPLANTATION; MEDICAL NEBULIZER; MENTAL DISEASE; NEBULIZATION; PATIENT COMPLIANCE; PEPTIC ULCER; POSTMENOPAUSE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; TUBERCULOSIS;

EID: 0141867859     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(03)00096-8     Document Type: Conference Paper

References (24)

1. American Medical Association 1998. Council of Scientific Affairs, Physician education of their patients about prescription medicines (Report 2).
2. Andersen O., Zweidorff O.K., Hjelde T., Rodland E.A. Problems when swallowing tablets. A questionnaire study from general practice [in Norwegian]. Tidsskr. Nor. Laegeforen. 20:1995;947-949.
3. Berlin I., Bisserbe J.-C., Eiber R., Balssa N., Sachon C., Bosquet F., Grimaldi A. Phobic symptoms, particularly the fear of blood and injury, are associated with poor glycemic control in type I diabetic adults. Diabetes Care. 20:1997;176-178.
4. Brunner G.A., Balent B., Ellmerer M., Siebenhofer A., Jendle J.H., Okikawa J., Pieber T.R. Dose-response relation of liquid aerosol inhaled insulin in type I diabetic patients. Diabetologia. 44:2001;305-308.
5. Cramer M.P., Saks S.R. Translating safety, efficacy and compliance into economic value for controlled release dosage forms. Pharmacoeconomics. 5:1994;482-504.
6. de Boer A.H., Le Brun P.P.H., van der Woude H.G., Hagedoorn P., Heijerman H.G.M., Frijlink H.W. Dry powder inhalation of antibiotics in cystic fibrosis therapy, part 1: development of a powder formulation with colistin sulfate for a special test inhaler with an air classifier as de-agglomeration principle. Eur. J. Pharm. Biopharm. 54:2002;17-24.
7. de Craen A.J.M., Tijssen J.G.P., de Gans J., Kleijnen J. Placebo effect in the acute treatment of migraine: subcutaneous placebos are better than oral placebos. J. Neurol. 247:2000;183-188.
8. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl. J. Med. 329:1993;977-986.
9. Doring G., Conway S.P., Heijerman H.G.M., Hodson M.E., Hoiby N., Smyth A., Touw D.J. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur. Respir. J. 16:2000;749-767.
10. Elliott W.J. Timing treatment to the rhythm of disease. A short course in chronotherapeutics. Postgrad. Med. 110:2001;119-129.
11. ® System: physiological and physicochemical factors influencing insulin effectiveness in healthy fasting subjects. Diabetes Technol. Ther. 2:2000;185-197.
12. French R.S., Cowan F.M., Mansour D.J.A., Morris S., Procter T., Hughes D., Robinson A., Guillebaud J. Implantable contraceptives (subdermal implants and hormonally impregnated intrauterine systems) versus other forms of reversible contraceptives: two systematic reviews to assess relative effectiveness, acceptability, tolerability and cost-effectiveness. Health Technol. Assess. 4:2000;1-107.
13. Gonda I., Schuster J.A., Rubsamen R.M., Lloyd P., Cipolla D., Farr S.J. Inhalation delivery systems with compliance and disease management capabilities. J. Control. Release (not in text). 53:1998;269-274.
14. Judge R. Patient perspectives on once-weekly fluoxetine. J. Clin. Psychiatry. 62:(Suppl. 22):2001;53-57.
15. Le Brun P.P.H., de Boer A.H., Mannes G.P.M., de Fraîture D.M.I., Brimicombe R.W., Touw D.J., Vinks A.A., Frijlink H.W., Heijerman H.G.M. Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients. Eur. J. Pharm. Biopharm. 54:2002;25-32.
16. Meijer W.E., Bouvy M.L., Heerdink E.R., Urquhart J., Leufkens H.G. Spontaneous lapses in dosing during chronic treatment with selective serotonin reuptake inhibitors. Br. J. Psychiatry. 179:2001;519-522.
17. Pilbrant Å., Cederberg C. Development of an oral formulation of omeprazole. Scand. J. Gastroenterol Suppl. 108:1985;113-120.
18. Prisant L.M. Hypertension and chronotherapy: shifting the treatment paradigm. Am. J. Hypertens. 14:2001;277S-279S.
19. Roose S.P., Holland P.J., Hassman H.A., Rosenthal M. Multi-site, open label, observational study of the effectiveness and safety of mirtazapine orally disintegrating tablets in depressed patients who are at least 50 years of age. Poster Presented at the 15th ECNP Congress, October 5-9, Barcelona: 2002.
20. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J. Pharm. Pharmacol. 50:1998;375-382.
21. Smolensky M.H., Haus E. Circadian rhythms and clinical medicine with applications to hypertension. Am. J. Hypertension. 14:2001;280S-290S.
22. UKPDS (UK Prospective Diabetes Study) Group, 1998. Intensive blood-glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 352:1998;837-853. [Published erratum in Lancet 354, 602].
23. van den Heuvel M.W., Kleijn H.J., Peeters P.A.M. Bioequivalence trial of orally disintegrating mirtazapine tablets and conventional oral mirtazapine tablets in healthy volunteers. Clin. Drug Invest. 21:2001;437-442.
24. www.cfs.org . Accessed November 2002.